Cooperative Agreement H1H8IHS0004

Award Date 9/30/22
Completion Date 9/29/24
Dollars Obligated $809K
Funding Federal Agency
Office of the Director
Federal Grant Program
93.228
Assistance Type
Cooperative Agreement
Place of Performance
Idaho, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research to improve understanding of digital cognitive markers for diagnosing and predicting cognitive health in Alzheimer's disease. The $441,612 award to Trustees of Boston University will support three key objectives: Comparing cross-sectional and longitudinal associations between the Life's Essential 8 (LE8) metrics and digital cognitive measures versus conventional neuropsychological...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $885,006 to Brigham & Women's Hospital Inc. to develop a smartphone-based point-of-care diagnostic system for detecting Alzheimer's disease-related biomarkers in blood plasma. The system will utilize microfluidics, nanotechnology, optical sensing, and deep learning to measure amyloid-beta, phosphorylated tau, and neurofilament light chain within 30 minutes, with the goal of creating an...
This $767,193 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports research to identify undiagnosed Alzheimer's disease (AD) in underserved Hispanic/Latino and African American populations. The key products and services to be delivered under this award include: Identifying disease trajectories associated with AD to help predict undiagnosed cases, while accounting for underdiagnosis bias in the target populations (Aims 1-2). Integrating...
This $1,177,500 federal Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) supports the Arizona State University (ASU) Roybal Center for Older Adults Living Alone with Cognitive Decline. The center will develop and conduct clinical trials of technology-enabled behavioral and lifestyle interventions to delay Alzheimer's disease and related dementias (ADRD) and improve quality of life in older adults living alone with cognitive decline,...
This $6.18 million project grant from the National Institutes of Health's National Institute on Aging will fund the University of Texas at Austin to conduct the first large-scale genomic analysis of continuous rates of longitudinal aging-related cognitive change prior to dementia onset. Working with sub-awardees the University of Colorado and the University of Edinburgh, the researchers will identify genetic variants beyond APOE that confer risk for cognitive decline leading to eventual...
This Project Grant award of $353,391.00, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to validate the use of a "Personal Learning Curve" paradigm as a sensitive marker of early memory decline related to Alzheimer's disease (AD) biomarkers in a large, diverse sample of older adults. The study seeks to determine if this digital cognitive assessment tool, which measures learning over repeated evaluations, can detect subtle AD-related memory failures...
This Project Grant award of $152,400 from the National Institute on Aging (CFDA 93.866 - Aging Research) will support a study to characterize the associations between intraindividual cognitive variability (IICV), longitudinal changes in magnetic resonance imaging (MRI) measures related to Alzheimer's disease and Alzheimer's disease-related dementia (AD/ADRD), and diabetes among older American Indians. The study aims to: 1) examine whether IICV is associated with neurodegenerative-related MRI...
The National Institute on Aging (NIA) awarded a $300,506 Project Grant under the Aging Research federal grant program (CFDA 93.866) to the University of Illinois to develop fair and interpretable large language models (LLMs) to detect Alzheimer's disease (AD) and mild cognitive impairment (MCI) from transcribed speech samples. The overarching goal is to advance healthcare through the innovative and responsible use of LLMs to recognize AD, MCI, and preclinical AD, prioritizing equity and...
The National Institute on Aging (NIA) awarded a $7,997,945 Project Grant (CFDA 93.866 - Aging Research) to The Regents of the University of California, San Francisco (UCSF) to support the "Advancing Diagnosis of Dementia in Primary Care Practice" (ADDPCP) project. This 5-year project aims to facilitate earlier and more accurate diagnosis of Alzheimer's disease and other neurodegenerative dementias in primary care settings. The project will implement a comprehensive diagnostic toolkit...
The New Mexico Aging and Long Term Services Department will receive $1.5 million through a three-year cooperative agreement award from the U.S. Department of Health and Human Services Administration for Community Living under the Alzheimer's Disease Program Initiative. The purpose of this funding is to support the development of a dementia-capable ecosystem of home and community-based services in New Mexico. Specifically, the Department will work to expand availability of supports and services...

EARLY DETECTION OF ALZHEIMER'S DISEASE IN NATIVE AMERICANS - PER THE NATIONAL INSTITUTE ON AGING, ALZHEIMER'S DISEASE IS CURRENTLY RATING TO THE SEVENTH LEADING CAUSE OF DEATH IN UNITED STATES AND IS THE MOST COMMON CAUSE OF DEMENTIA IN OLDER ADULTS. DEMENTIA IS THE LOSS OF COGNITIVE FUNCTIONING-THINKING, REMEMBERING AND REASONING-AND BEHAVIORAL ABILITIES TO SUCH AN EXTENT THAT IT INTERFERES WITH A PERSON'S DAILY LIFE AND ACTIVITIES. DEMENTIA RANGES IN SEVERITY FROM THE MILD TO STAGE, WHEN IT IS JUST BEGINNING TO AFFECT A PERSON'S FUNCTIONING, TO THE MOST SEVERE STAGE, WHEN THE PERSON MUST DEPEND COMPLETELY ON OTHERS FOR HELP WITH BASIC ACTIVITIES OF DAILY LIVING. THE CAUSES OF DEMENTIA CAN VARY, DEPENDING ON THE TYPE OF BRAIN CHANGES THAT MAY BE TAKING PLACE. OTHER DEMENTIAS INCLUDE LEWY BODY DEMENTIA, FRONTOTEMPORAL DISORDERS AND VASCULAR DEMENTIA. IT IS COMMON FOR PEOPLE TO HAVE MIXED DEMENTIA-A COMBINATION OF 2 OR MORE TYPES OF DEMENTIA. WITH THE PREVALENCE OF DIABETES AND INDIAN COUNTRY, MIXED DEMENTIA IS A SIGNIFICANT ISSUE. EARLY DETECTION OF DEMENTIA WILL ASSIST IN RISK REDUCTION AND POSSIBLY SLOW DOWN PROGRESSION OF DEMENTIA. MEMORY PROBLEMS ARE TYPICALLY ONE OF THE FOR SIGNS OF COGNITIVE IMPAIRMENT RELATED TO ALZHEIMER'S DISEASE. DEMENTIA AND OTHER FORMS OF COGNITIVE IMPAIRMENT OFTEN GO UNDIAGNOSED. THE COGNITIVE FUNCTION ASSESSMENT BEING RECOMMENDED DURING ANNUAL WELLNESS EXAMS MAY ASSIST TO IDENTIFY EARLY CLINICAL CHANGES THAT MAY INDICATE COGNITIVE DECLINE AND BRAIN CHECK IS A COMPREHENSIVE COGNITIVE HEALTH PLATFORM TO ASSESS, QUICKLY AND EASILY, COGNITIVE FUNCTION WHICH WILL ULTIMATELY NEED TO HIGH-QUALITY PATIENT CARE. THE DEVELOPMENT OF A PROGRAM TO IDENTIFY COGNITIVE DECLINE AT ITS EARLIEST ONSET WILL ASSIST IN SUPPORTING AND EDUCATING OUR PATIENTS AND THEIR FAMILIES ON HOW TO BEST PREPARE AND CARE FOR OUR ELDERS AS THEY AGE.

Posted 9/26/22, 12:00 AM